Robert Nelsen's Net Worth

$16.7 Million

Who is Robert Nelsen?

Robert Nelsen has an estimated net worth of $16.7 Million. This is based on reported shares across multiple companies, which include PHASERX, INC., Neumora Therapeutics, Inc., ADESTO TECHNOLOGIES Corp, IMPINJ INC, VBI VACCINES INC., NeurogesX Inc, Receptos, Inc., Gossamer Bio, Inc., Scholar Rock Holding Corp, Erasca, Inc., Pulmatrix, Inc., Verve Therapeutics, Inc., bluebird bio, Inc., Metacrine, Inc., Unity Biotechnology, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., Homology Medicines, Inc., Achaogen Inc, Trubion Pharmaceuticals, Inc, Beam Therapeutics Inc., Syros Pharmaceuticals, Inc., XTERA COMMUNICATIONS, INC., CELEBRATE EXPRESS, INC., Boundless Bio, Inc., Rapport Therapeutics, Inc., Sana Biotechnology, Inc., KYTHERA BIOPHARMACEUTICALS INC, ALNYLAM PHARMACEUTICALS INC, Lyell Immunopharma, Inc., AGIOS PHARMACEUTICALS INC, DA32 Life Science Tech Acquisition Corp., 908 Devices Inc., Karuna Therapeutics, Inc., Quanterix Corp, Revolution Healthcare Acquisition Corp., Denali Therapeutics Inc., FATE THERAPEUTICS INC, Twist Bioscience Corp, Sage Therapeutics, Inc., Vir Biotechnology, Inc., Bellerophon Therapeutics, Inc., XCYTE THERAPIES INC, Juno Therapeutics, Inc., Prime Medicine, Inc., ILLUMINA INC, and ADOLOR CORP.

SEC CIK

Robert Nelsen's CIK is 0001219042

Past Insider Trading and Trends

2021 was Robert Nelsen's most active year for acquiring shares with 24 total transactions. Robert Nelsen's most active month to acquire stocks was the month of May. 2018 was Robert Nelsen's most active year for disposing of shares, totalling 5 transactions. Robert Nelsen's most active month to dispose stocks was the month of February. 2015 saw Robert Nelsen paying a total of $1,126,371.76 for 206,673 shares, this is the most they've acquired in one year. In 2018 Robert Nelsen cashed out on 90,058 shares for a total of $6,326,766.00, their largest year based on trade value.